ArticleClinical cancer research : an official journal of the American Association for Cancer Research2009
Pharmacologic unmasking of epigenetically silenced genes in breast cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 70 citations in OpenAlex.
- Phillygenin suppresses hepatocellular carcinoma progression by modulating the TNF signaling pathway and TCA cycle metabolism.Frontiers in pharmacology · 2026Article
- Research advances of MAL family members in tumorigenesis and tumor progression (Review).Molecular medicine reports · 2024Review
- Reduced expression of secretogranin VGF in laryngeal squamous cell carcinoma.Oncology letters · 2024Article
- Oxoglutarate dehydrogenase-like inhibits the progression of hepatocellular carcinoma by inducing DNA damage through non-canonical function.Cell death and differentiation · 2023Article
- Impact of FKBP52 on cell proliferation and hormone-dependent cancers.Cancer science · 2023Review
- The MAL Family of Proteins: Normal Function, Expression in Cancer, and Potential Use as Cancer Biomarkers.Cancers · 2023Review
- The impact of RNA binding proteins and the associated long non-coding RNAs in the TCA cycle on cancer pathogenesis.RNA biology · 2023Review
- Transcriptome Based Estrogen Related Genes Biomarkers for Diagnosis and Prognosis in Non-small Cell Lung Cancer.Frontiers in genetics · 2021Article
- Bioinformatics Analysis of KIF1A Expression and Gene Regulation Network in Ovarian Carcinoma.International journal of general medicine · 2021Article
- OGDHL closely associates with tumor microenvironment and can serve as a prognostic biomarker for papillary thyroid cancer.Cancer medicine · 2021Article
- Activation of Mitochondrial 2-Oxoglutarate Dehydrogenase by Cocarboxylase in Human Lung Adenocarcinoma Cells A549 Is p53/p21-Dependent and Impairs Cellular Redox State, Mimicking the Cisplatin Action.International journal of molecular sciences · 2020Article
- Discovery of rare coding variants in OGDHL and BRCA2 in relation to breast cancer risk in Chinese women.International journal of cancer · 2020Article
- Synthetic analogues of 2-oxo acids discriminate metabolic contribution of the 2-oxoglutarate and 2-oxoadipate dehydrogenases in mammalian cells and tissues.Scientific reports · 2020Article
- Construction and Validation of a 13-Gene Signature for Prognosis Prediction in Medulloblastoma.Frontiers in genetics · 2020Article
- Biological Actions of the Hsp90-binding Immunophilins FKBP51 and FKBP52Biomolecules · 2019Review
- Article
- Review
- The emerging role and targetability of the TCA cycle in cancer metabolism.Protein & cell · 2018Review
- Elevated FKBP52 expression indicates a poor outcome in patients with breast cancer.Oncology letters · 2017Article
- Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer.BMC genomics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
purposeAberrant promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the pathogenesis of various cancers including breast cancer. Many epigenetically inactivated genes involved in breast cancer development remain to be identified. Therefore, in this study we used a pharmacologic unmasking approach in breast cancer cell lines with 5-aza-2'-deoxycytidine (5-aza-dC) followed by microarray expression analysis to identify epigenetically inactivated genes in breast cancer. EXPERIMENTAL
designBreast cancer cell lines were treated with 5-aza-dC followed by microarray analysis to identify epigenetically inactivated genes in breast cancer. We then used bisulfite DNA sequencing, conventional methylation-specific PCR, and quantitative fluorogenic real-time methylation-specific PCR to confirm cancer-specific methylation in novel genes.
resultsForty-nine genes were up-regulated in breast cancer cells lines after 5-aza-dC treatment, as determined by microarray analysis. Five genes (MAL, FKBP4, VGF, OGDHL, and KIF1A) showed cancer-specific methylation in breast tissues. Methylation of at least two was found at high frequency only in breast cancers (40 of 40) as compared with normal breast tissue (0 of 10; P<0.0001, Fisher's exact test).
conclusionsThis study identified new cancer-specific methylated genes to help elucidate the biology of breast cancer and as candidate diagnostic markers for the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.